Indications:
- Relatro is indicated for controlling clinical spasticity in conditions like spinal cord injury, stroke, cerebral palsy, or multiple sclerosis, aiding functional rehabilitation.
- It’s beneficial for patients with reversible spasticity, showing improvement in clonus and reducing the need for nursing care.
Pharmacology:
- Dantrolene in Relatro affects skeletal muscle contractile response beyond the myoneural junction, disrupting excitation-contraction coupling.
- It targets skeletal muscle, interfering with the release of Ca++ from the sarcoplasmic reticulum, inducing relaxation.
Dosage & Administration:
- Adults: Start with 25 mg twice daily, gradually titrating up to a maximum of 400 mg/day. Pediatric dosing varies.
- For malignant hyperthermia prevention, administer 4 to 8 mg/kg/day preoperatively and post-crisis.
Interaction:
- Relatro may cause drowsiness, exacerbated by CNS depressants. Hepatotoxicity risk increases with concomitant estrogen therapy.
Contraindications:
- Avoid in active hepatic diseases like hepatitis and cirrhosis.
Side Effects:
- Common side effects include drowsiness, dizziness, weakness, and diarrhea, often transient and manageable with dose adjustment.
Pregnancy & Lactation:
- Use during pregnancy (Category C) and lactation only if benefits outweigh risks.
Precautions & Warnings:
- Monitor liver function; discontinue if no improvement within 45 days.
- Caution in driving, hazardous occupations, and exposure to sunlight.
- Consider hepatocellular injury risks, especially in females and patients over 35 years.
Special Populations:
- Long-term safety not established in pediatric patients under 5 years.
Therapeutic Class:
- Centrally acting Skeletal Muscle Relaxants
Storage Conditions:
- Store in a cool, dry place, protected from light.
Reviews
There are no reviews yet.